Inicio › Enfermedad de células falciformes › Texas
Ensayos clínicos de Enfermedad de células falciformes en Texas
13 estudios sobre Enfermedad de células falciformes buscan participantes en Texas.
Ciudades en Texas
Texto oficial del estudio (inglés)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Texas Childrens Cancer and Hematology Center, Houston
- U of TX Health Science Ct, Houston
ReclutandoFase 3
Edades de 12 a 100 · Todos los sexos · Actualizado el 10 nov 2026 · NCT06439082Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- UT Physicians Comprehensive Adult Sickle Cell Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07224360A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
- University of Texas Health Science Center at Houston, Houston
ReclutandoFase 3
Edades de 12 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT07656415A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- UT Health Science Center, Houston
ReclutandoFase 1/2Se aceptan voluntarios sanos
Edades de 12 a 55 · Todos los sexos · Actualizado el 27 oct 2026 · NCT06546670The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Baylor College of Medicine- Site Number : 8400055, Houston
- UT Physicians - Memorial Hermann- Site Number : 8400052, Houston
ReclutandoFase 3
Edades de 10 a 65 · Todos los sexos · Actualizado el 15 oct 2026 · NCT06975865A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Texas Children's Hospital_Houston, Houston
- UT Health University of Texas, Houston
ReclutandoFase 3
Edades de 2 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- UT Health University of Texas, Houston
ReclutandoFase 3
Edades de 12 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT06612268ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Children's Blood and Cancer Center of Central Texas, Austin
- North Texas Hemophilia and Thrombosis Program - Pediatric Program / Center for Cancer & Blood Disorders, Dallas
- North Texas Comprehensive Hemophilia Treatment Center, Dallas
- y 3 más
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 17 ago 2026 · NCT04398628Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Texas Children's Hopsital (NT-DMT), Houston
- Texas Children's Hospital (MRD-HCT), Houston
- UT San Antonio (NT-DMT), San Antonio
ReclutandoEstudio observacional
Edades de 3 a 20 · Todos los sexos · Actualizado el 4 jun 2026 · NCT06941389Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
- Site # 8400004, Houston
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 15 abr 2026 · NCT07247188Sickle Cell Kidney Biorepository
- Parkland Memorial Hospital, Dallas
- University of Texas Southwestern Medical Center, Dallas
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 18 a 65 · Todos los sexos · Actualizado el 13 abr 2026 · NCT07064174Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
- Baylor College of Medicine, Houston
ReclutandoFase 2
Edades de 15 a 40 · Todos los sexos · Actualizado el 13 mar 2026 · NCT06260891Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Texas at Houston, Houston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jun 2025 · NCT06385886De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.